GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Acamprosate

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Preserved original GlobalRPh source

Product / population
Preserved historical content; not revalidated as current prescribing guidance.
Renal method
Read the measure and population stated in the original source sections.
Source revision
Historical source date not established
Retrieved
2026-09-05
Local review status
Historical source retained. Not current-label validation.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Exact CrCl 30: the contraindication must not be hidden

The original GlobalRPh section prints a below-30 contraindication. The RX mirror explicitly includes 30 in its contraindication while also printing 30-50 in the reduced-dose band.

What to reconcile: Do not use the overlapping band as permission at exactly 30. Keep the explicit contraindication visible and obtain current product-specific adjudication.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Historical

Preserved original GlobalRPh source

Open original reference

GlobalRPh · Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Source date: Historical source date not established
Retrieved: 2026-09-05

Historical source retained. Not current-label validation.

Usual Dosing (Adults)

Alcohol abstinence: 666 mg (2 tabs) orally tid.

GRPH-acamprosate-01 · Source locator: Usual Dosing (Adults)

Renal Dosing

[>50 ml/min]: No changes

[30-50]: 333 mg tid.

[<30]: Contraindicated.

GRPH-acamprosate-02 · Source locator: Renal Dosing

Hemodialysis

Contraindicated

GRPH-acamprosate-03 · Source locator: Hemodialysis

Source identity and provenance
Source
https://globalrph.com/renal/acamprosate/
Retrieved
2026-09-05
Renal-function method
Read the measure and population stated in the original source sections.
Source date/version
Historical source date not established

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=acamprosate&s1=original&h1=08aedc7d2ef065137160a798f8d8c660d0593273900e3c7c3d064217b54389b3